← Back to Search

One: Patient population with hepatic lesion(s) for Liver Disease

Phase 4
Waitlist Available
Led By Jordan K Swennson, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two years
Awards & highlights

Study Summary

This trial compares the effectiveness of two imaging methods in distinguishing between two types of liver lesions.

Eligible Conditions
  • Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~two years
This trial's timeline: 3 weeks for screening, Varies for treatment, and two years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
new method diagnosing hepatic lesions

Trial Design

1Treatment groups
Experimental Treatment
Group I: One: Patient population with hepatic lesion(s)Experimental Treatment1 Intervention
Patient scheduled to get MRI will also be asked to receive an ultrasound of the liver
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
1,2-Distearoyllecithin
FDA approved

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
993 Previous Clinical Trials
1,095,236 Total Patients Enrolled
Jordan K Swennson, MDPrincipal InvestigatorIndiana University
~8 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top